3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
5
Phase 1
4
Phase 3
2
Phase 4
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gynecologic
1
Breast
1
Conditions
Ovarian Neoplasms
29
Fallopian Tube Neoplasms
15
Breast Neoplasms
10
Carcinoma, Ovarian Epithelial
6
Peritoneal Neoplasms
3
Multiple Myeloma
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Neoplasms
2
Neoplasm Metastasis
2
Lymphoma, T-Cell, Peripheral
2
Lymphoma, Large B-Cell, Diffuse
2
Vaccinia
1
Uterine Cervical Neoplasms
1
Sarcoma, Kaposi
1
Pelvic Neoplasms
1
Neoplasms, Plasma Cell
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma
1
Low Grade Serous Ovarian Cancer
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Genital Neoplasms, Female
1
Genetic Predisposition to Disease
1
Endometrial Neoplasms
1
Carcinoma
1
Acquired Immunodeficiency Syndrome
1
AIDS-related Kaposi sarcoma
1
Interventions
Leucovorin
22
Fluorouracil
22
Paclitaxel
21
Gemcitabine
21
Docetaxel
21
Capecitabine
21
Irinotecan
16
Carboplatin
15
Radiosurgery
14
Oxaliplatin
13
Cisplatin
13
Bevacizumab
13
Zoledronic Acid
12
pembrolizumab
11
Radiotherapy
11
Fulvestrant
11
palbociclib
9
Pemetrexed
9
Drug Therapy
9
130-nm albumin-bound paclitaxel
9
Surgical Procedures, Operative
7
Letrozole
7
Ibandronic Acid
7
abemaciclib
6
Trastuzumab
6
Prednisone
6
Vinorelbine
5
Folfox protocol
5
Floxuridine
5
Doxorubicin
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
Neoplasm Metastasis
×
liposomal doxorubicin
×
Clear all
NCT07213804
2026-05-27
FRAmework-01
Eli Lilly and Company
Phase 3
Recruiting
1,080 enrolled
NCT04895358
2026-03-11
KEYNOTE-B49
Merck Sharp & Dohme LLC
Phase 3
Active not recruiting
340 enrolled